Your session is about to expire
← Back to Search
TVB-2640 for Non-Small Cell Lung Cancer
This trial will test a new cancer drug, TVB-2640, on patients with a specific type of non-small cell lung cancer.
- KRAS Gene Mutation
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 25 Patients • NCT03032484
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have had a previous allergic reaction or lung inflammation caused by medication, radiation, or an immune response.You have had or currently have another type of cancer that could affect the safety or effectiveness of the new treatment being tested.You are allergic to any parts of the medication TVB-2640.
- Group 1: TVB-2640
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the goals that researchers hope to achieve with this clinical trial?
"The main goal of this trial is to assess the disease control rate of TVB-2640 over the course of a year. Secondary objectives include assessing the mean change in sebaceous secretion of fatty acids, safety profile of TVB-2640, and mean change in fasting plasma lipidomics."
How many people are taking part in this clinical trial?
"That is correct, the clinical trial is still looking for patients. The public information on the website was first posted on September 11th, 2019 and updated February 3rd, 2022. At this time, they are enrolling 12 individuals between 2 locations."
Are people with the relevant medical condition able to participate in this trial currently?
"That is correct, the online clinicaltrials.gov database has information stating that this trial is still recruiting patients. The 12 subjects needed for this study are being recruited from 2 medical facilities, and the trial was first posted on September 11th, 2019 with its most recent edit on February 3rd, 2022."
Is TVB-2640 able to be legally prescribed by doctors in the United States?
"TVB-2640 is currently in Phase 2 of clinical trials. While there is some evidence supporting its safety, there is none yet to suggest that it is an effective medication."
Share this study with friends